Banning WuXi is more complicated than it might sound
A congressional bill is meant to effectively ban certain Chinese life sciences companies from doing business in the U.S. But actually going through with it risks seriously hobbling the companies…
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Hello, everyone. Damian here with a curious case before the FDA, a State of the Union preview, and the latest IPO to test biotech’s recent resurgence.
What's Your Reaction?
